 
            IndraLab
Statements
                                      reach
                                
                                  
                                
                                
          
          
                                  "These results support the hypothesis that TP53 mutations play a role in the late stage of tumorigenesis, such as progression step of adenomas to invasive adenocarcinomas or metastasis to distant organs.Cellular stress, like DNA damage, telomere erosion, hypoxia, and nutrient depletion, as well as oncogenic signaling, activates p53, leading to the promotion of cell-cycle arrest, senescence, and apoptosis depending on the extent and context of the stress (Vousden and Lu, 2002; Vousden and Prives, 2009)."
          
                              
          
                               
                            
                                      reach
                                
                                  
                                
                                
          
          
                                  "EOC cells are presumably vulnerable to the inhibition of S- and G  /M-phase DNA damage checkpoints, owing to the aberrant p53 signaling caused by TP53 mutation, the predominant genetic alteration in human EOC that abrogates the G   checkpoint and renders EOC cells more dependent on S- and G  /M-phase DNA damage checkpoints (15)."
          
                              
          
                               
                            
                                      reach
                                
                                  
                                
                                
          
          
                                  "More significantly, Ser20 phosphorylation of specific p53 mutants with oxali-Pt also activates p53 function, and this raises the likelihood that other p53 mutants in refractory human ovarian cancers could also be functionally activated with distinct drugs, such as oxali-Pt, to restore therapeutic sensitivity."
          
                              
          
                               
                            
                                      reach
                                
                                  
                                
                                
          
          
                                  "Further supporting these data, we show that acetylation-mimicking mutation of p53 results in a decrease in S367p, which could, in fact, be an indispensable event for enhancing the stability of p53, increasing the recruitment of p53 to target genes, and activating the transcriptional function of p53 upon DNA damage."
          
                              
          
                               
                            
                                      reach
                                
                                  
                                
                                
          
          
                                  "The inactivation of the p53 protein induced by TP53 mutations is considered to be the initiator of the genomic instability, cell-cycle activation, and malignant biological behaviors of UC.1 2 In our previous study, TP53 disruptive mutation, causing p53 protein loss of function, was found to be associated with poor prognosis and invasive subtype transformation in patients with UC."
          
                              
          
                               
                            
                                      reach
                                
                                  
                                
                                
          
          
                                  "These findings should be kept on the horizon and studied on a larger scale to determine whether or not this is clinically significant and whether patients acquire de novo TP53 mutations with idasanutlin treatment.There are also early phase trials ongoing evaluating APR-246 (eprenetapopt), a small molecule that restores wild-type p53 functions in TP53-mutant cells."
          
                              
          
                               
                            
                                      reach
                                
                                  
                                
                                
          
          
                                  "In this scenario, it is not surprising that the alterations of p53 activity caused by different TP53 mutations can result in a dysregulated senescence and tumor secretome, affecting the complex crosstalk between tumor cells and a plethora of cell types in the surrounding stromal microenvironment."